ATTO (Attovia Therapeutics) Beginning Cash Position: $40.60 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATTO Attovia Therapeutics Inc ATTO
8 GF Score
Price $20.38
View Full Analysis

What is Attovia Therapeutics Beginning Cash Position?

Attovia Therapeutics ATTO -6.94% 8 Beginning Cash Position is $40.60 Mil as of Mar. 2026. GuruFocus rates ATTO with a GF Score™ of 8/100.

Attovia Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $40.60 Mil.

Attovia Therapeutics's quarterly Beginning Cash Position declined from Mar. 2025 ($31.24 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($40.60 Mil).

Attovia Therapeutics's annual Beginning Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($23.33 Mil) and increased from Dec. 2024 ($23.33 Mil) to Dec. 2025 ($31.24 Mil).

Attovia Therapeutics Beginning Cash Position Related Terms

Attovia Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Attovia Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Attovia Therapeutics Beginning Cash Position Chart

Attovia Therapeutics Annual Data
Trend Dec24 Dec25
Beginning Cash Position
23.33 31.24

Attovia Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
Beginning Cash Position 0.00 31.24 0.00 40.60
ATTO
8GF Score
Attovia Therapeutics Inc ATTO
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Attovia Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $40.60 Mil mean?
Attovia Therapeutics (ATTO) has a Beginning Cash Position of $40.60 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Attovia Therapeutics and its competitors.
Is Attovia Therapeutics' Beginning Cash Position too high?
Attovia Therapeutics' current Beginning Cash Position is $40.60 Mil. Overall, Attovia Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Attovia Therapeutics' Beginning Cash Position compare to ?
Attovia Therapeutics' Beginning Cash Position of $40.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Attovia Therapeutics and its competitors. Attovia Therapeutics's current Beginning Cash Position is $40.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Attovia Therapeutics stock overvalued right now?
Attovia Therapeutics (ATTO) has a current Beginning Cash Position of $40.60 Mil. The current Beginning Cash Position is $40.60 Mil. Attovia Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Attovia Therapeutics (ATTO), the current Beginning Cash Position is $40.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Attovia Therapeutics Business Description

Comparable Companies
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
8GF Score

Get the complete analysis for ATTO

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.38
Price